Results 221 to 229 of about 53,966 (229)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Lancet, The, 2023
exaly  

Sorafenib for Advanced and Refractory Desmoid Tumors

New England Journal of Medicine, 2018
Abha A Gupta, Richard F Riedel, Natally Horvat   +2 more
exaly  

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Lancet, The, 2016
Keith T Flaherty, Christopher G Wood, Michael Jewett   +2 more
exaly  

Sorafenib

Reactions Weekly, 2018
openaire   +2 more sources

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

Nature Medicine, 2014
Ramona Rudalska, Daniel Dauch, Thomas Longerich   +2 more
exaly  

A case of variant angina in a patient under chronic treatment with sorafenib

Nature Reviews Clinical Oncology, 2010
Italo Porto, Luca Miele, Maurizio Pompili   +2 more
exaly  

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Nature Medicine, 2018
Lukas Braun, David O'Sullivan, Simone Thomas   +2 more
exaly  

Sorafenib

Reactions Weekly
openaire   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Lancet, The
exaly